Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Migraine Nasal Spray Market size was valued at USD 536.33 million in 2024 and is likely to cross USD 1.26 billion by 2037, registering more than 6.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of migraine nasal spray is estimated at USD 567.33 million.
The market growth can be attributed to growing prevalence of migraine, backed by the increased stress, depression, sleep deprivation, and anxiety prevalent amongst the population. In fact, migraine is the third most common disease, and approximately 1 billion people suffer from migraine worldwide. Furthermore, scientists suggest that humans are facing extreme weather changes, which can aggravate their health, making diseases, such as, migraine a common phenomenon. According to the World Meteorological Organisation, [R1] the decade 2011-2020 was the warmest on record, and the year 2020 is among the three warmest years globally. The increasing adulteration in food, hormonal misbalance, and longer screen time are also major reasons behind the growing number of migraine patients. Scientists have also found that migraine is more pervasive in women owing to hormonal changes, as 8 out of 10 people with migraine are women. As the number of patients with migraine is increasing exponentially, people are seeking an efficient remedy to eradicate the excruciating pain, which is expected to expand the global migraine nasal spray market.

Migraine Nasal Spray Sector: Growth Drivers and Challenges
Growth Drivers
- Changing Lifestyle of People
- Increase in Stress, Anxiety, and Consumption of Adulterated Food
Challenges
- Higher Adoption of Medicine over Spray
- Side Effects, such as, Dry and Burning Eyes, and Sore Throat
Migraine Nasal Spray Market: Key Insights
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
6.8% |
Base Year Market Size (2024) |
USD 536.33 million |
Forecast Year Market Size (2037) |
USD 1.26 billion |
Regional Scope |
|
Migraine Nasal Spray Segmentation
The global migraine nasal spray market is segmented by drug type into ergotamine dihydroergotamine, ketorolac, and zolmitriptan, out of which the zolmitriptan segment is anticipated to hold the largest share in the market over the forecast period on account of the low cost and higher efficiency of the drug. Also, the manufacturers of zolmitriptan have tried to nullify the side effects caused by the usage of migraine nasal spray making the product popular amongst people.
Our in-depth analysis of the global migraine nasal spray market includes the following segments
By Drug Type |
|
By Distribution Channel |
|
By Dosage
|
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportMigraine Nasal Spray Industry - Regional Synopsis
North America Market Statistics
Regionally, the global migraine nasal spray market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. North America industry is anticipated to hold largest revenue share by 2037, impelled by increasing cases of migraine, raising awareness, and developing health care infrastructure. According to the report published in U.S. National Library for Medicine, migraine continues to be an important public health problem prevalent among 15.9% of all adults in the year 2018. Moreover, around 40% of US adults with migraine were unemployed in the same year. Hence, the governments in developed nations are addressing the disadvantages of migraines and making people aware of remedies, such as, migraine nasal spray, which is estimated to boost the market growth.
APAC Market Analysis
The migraine nasal spray market in the Asia Pacific region is expected to expand significantly over the forecast period. Highly populated countries such as India, China, and others, are estimated to offer a large consumer base for migraine nasal sprays, owing to the increasing cases of migraine in the region.

Companies Dominating the Solar Cell Landscape
- Upsher-Smith Laboratories, LLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Dr. Reddy’s Laboratories Ltd.
- AstraZeneca PLC
- GlaxoSmithKline plc
- Leucadia Pharmaceuticals (Custopharm, Inc.)
- Assertio Therapeutics, Inc
- Cipla Inc.
- Impel Neuro Pharma.Inc
- Tonix Pharmaceuticals Holding Corp.
- Amneal Pharmaceuticals LLC
In the News
-
March 22, 2022: Impel NeuroPharma, the manufacturer of migraine nasal spray Trudhesa, presented drug performance data at the 2022 scientific meeting of the American Academy of Neurology. The latest data shows rapid and consistent migraine relief with Trudhesa treatment.
Author Credits: Radhika Pawar
- Report ID: 4059
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT